Efficacy & Safety Study of YH22162 vs Telmisartan/Amlodipine in Patients With Hypertension Inappropriately Controlled on Telmisartan/Amlodipine Treatment
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 381 participants.
Also called NCT02620163
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 381 participants
- Sponsor
- Registry
-
NCT02620163
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT02620163. Randomized; double masking; primary purpose treatment. Start 2015-12 (actual); primary completion 2016-12 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy & Safety Study of YH22162 vs Telmisartan/Amlodipine in Patients With Hypertension Inappropriately Controlled on Telmisartan/Amlodipine Treatment
- Condition
- Hypertension
- Intervention (Drug)
- telmisartan/amlodipine 40/5mg
- Intervention (Drug)
- YH22162 40/5/12.5 mg
- Intervention (Drug)
- telmisartan/amlodipine 80/5mg
- Intervention (Drug)
- YH22162 80/5/25 mg
- Intervention (Drug)
- telmisartan/amlodipine 40/5mg placebo
- Intervention (Drug)
- YH22162 40/5/12.5 mg placebo
- Intervention (Drug)
- telmisartan/amlodipine 80/5mg placebo
- Intervention (Drug)
- YH22162 80/5/25 mg placebo
- Lead sponsor
- Yuhan Corporation
Record details
- Record id
cardio:ct-nct02620163- Content hash
18df5e9c80975a9100651590659c4f4f8f26764c65f9f5275881fc3bb7350ba7